Weight loss drugs Ozempic and Wegovy would no longer be covered by California's health insurance for low-income people under ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

The analysis of 11 weight-loss drug studies by the University of Oxford found that patients typically lost 8kg (18lb) after ...

Scientists herald 150 new jabs and pills to tackle obesity going through the research pipeline - but issue urgent warning to ...

Weight-loss jabs have been hailed as the key to longer life even if you are not overweight, according to experts.

Key Takeaways More U.S. teens are getting weight-loss surgeryThe procedures increased 15% between 2021 and 2023At the same ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Weight-loss drugs like Ozempic and Wegovy could usher in a “golden age” of medicine due to their ability to delay diseases associated with ageing.

Studies have shown that GLP-1s reduce inflammation in the brain and regulate anxiety as well as depression. When insurance ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...